Mandel J, Kjellstrand C M
Nephron. 1986;44(2):111-4. doi: 10.1159/000183977.
We analyzed long-term, 2- to 9-year results and risk factors in 13 patients treated with dialysis and transplantation for hypernephroma. Eight were dialyzed only, 6 died, 4 of them from metastatic disease that occurred in less than 8 months in 3. Five patients were also transplanted. Three died, 1 of metastatic disease. Two are alive, 1 with metastatic disease, 6 years after transplant, 3 years after diagnosis of metastasis. There were no differences in age and sex in those with early metastatic disease when compared to those without, but stage III-IV disease and time of less than 5 years between first and second nephrectomy were more common in those with early metastatic disease. These data indicate that a 7-month waiting time on dialysis is enough to avoid transplanting those with early recurrence, and that patients with stage III-IV and early reappearance of tumor in the second kidney are best treated with conservative management rather than a second total nephrectomy.
我们分析了13例接受透析和移植治疗的肾细胞癌患者的长期(2至9年)结果及危险因素。8例仅接受透析治疗,6例死亡,其中4例死于转移性疾病,3例在不到8个月内发生转移。5例患者还接受了移植手术。3例死亡,1例死于转移性疾病。2例存活,1例有转移性疾病,移植后6年,转移诊断后3年。早期发生转移性疾病的患者与未发生者在年龄和性别上无差异,但III-IV期疾病以及首次和第二次肾切除间隔时间少于5年在早期发生转移性疾病的患者中更为常见。这些数据表明,透析7个月的等待时间足以避免移植早期复发的患者,并且对于III-IV期且第二肾出现早期肿瘤复发的患者,采用保守治疗而非再次全肾切除术是最佳治疗方法。